InflammopharmacologyPub Date : 2025-03-01Epub Date: 2024-12-17DOI: 10.1007/s10787-024-01620-x
Jiachuan Li, Hu Hu, Xin Xu, Dan Zhu, Yisheng Chen, Laiming Li
{"title":"Mechanisms of action of ethyl acetate fractions of Liparis nervosa (Thunb.) Lindl. as potential central anti-nociceptive agents.","authors":"Jiachuan Li, Hu Hu, Xin Xu, Dan Zhu, Yisheng Chen, Laiming Li","doi":"10.1007/s10787-024-01620-x","DOIUrl":"10.1007/s10787-024-01620-x","url":null,"abstract":"<p><p>Opioids/non-steroidal anti-inflammatory drugs are used to alleviate pain; however, they are expensive and can have adverse effects, especially when used over extended periods. Therefore, there is immense demand for innovative, non-addictive analgesics. Here, we report a novel plant-derived central anti-nociceptive agent, Liparis nervosa (Thunb.) Lindl. (LN), validated in animal pain models. Ethyl acetate fractions of L. nervosa (EALN) exhibited central anti-nociceptive activity in hot plate, tail immersion, formalin-induced paw oedema, and acetic acid-induced abdominal writhing tests. The chemical composition of the EALN was determined using ultra-high-performance liquid chromatography-mass spectrometry. Reserpine (monoamine transmitter-depleting agent) and naltrexone (opioid antagonist) partially suppressed the anti-nociceptive effect of EALN in both phases of the formalin test. Oral administration of EALN activated the endogenous opioid and central descending inhibitory systems by increasing β-endorphin, 5-hydroxytryptamine, and norepinephrine expression. EALN treatment increased the expression of γ-aminobutyric acid B; inhibited the expression of prostaglandin E2, substance P, calcitonin gene-related peptide, and c-Fos; and blocked the transmission of pain signals in the spinal cord. EALN treatment reduced the activity of nitric oxide and nitric oxide synthase in the central region and inhibited the nitric oxide-cyclic guanosine monophosphate signal transduction pathway, thereby attenuating the transmission of nociceptive information in the descending inhibitory pathways. The central anti-nociceptive effect of EALN was achieved by integrating these pathways. This study provides new insights into the pharmacologic action of LN and provide a therapeutic approach as a promising candidate for central anti-nociceptive agents.</p>","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":"1455-1471"},"PeriodicalIF":4.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142835614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
InflammopharmacologyPub Date : 2025-03-01Epub Date: 2025-02-16DOI: 10.1007/s10787-025-01653-w
Syeda Asloob Fatima, Bushra Akhtar, Ali Sharif, Muhammad Imran Khan, Muhammad Shahid, Fozia Anjum, Fatma Hussain, Aisha Mobashar, Maham Ashraf
{"title":"Implications of nociceptor receptors and immune modulation: emerging therapeutic targets for autoimmune diseases.","authors":"Syeda Asloob Fatima, Bushra Akhtar, Ali Sharif, Muhammad Imran Khan, Muhammad Shahid, Fozia Anjum, Fatma Hussain, Aisha Mobashar, Maham Ashraf","doi":"10.1007/s10787-025-01653-w","DOIUrl":"10.1007/s10787-025-01653-w","url":null,"abstract":"<p><p>Chronic painful autoimmune disorders such as multiple sclerosis (MS), inflammatory bowel disease (IBD), and rheumatoid arthritis (RA) induce significant discomfort. They are defined by persistent inflammation and immune-mediated tissue injury. The activation and sensitisation of nociceptors, mutated in various disorders, are fundamental components contributing to the pain experienced in these conditions. Recent discoveries indicate that immunological mediators and nociceptive receptors interact functionally within peripheral and central sensitisation pathways, amplifying chronic pain. This research examines the involvement of nociceptors in rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease. It explores how immune cells and pro-inflammatory cytokines induce, sensitise and regulate various nociceptive receptors (P2X, TRPA1 and TRPV1). Finally, we address possible future directions with respect to the treatment of long-lasting effects on immunity, and what new drug targets could be pursued as well, in order to counteract such either neuro-immune interactions in conditions involving the immunological system. By studying nociceptive mechanisms across autoimmune illnesses, we want to identify shared pathways and activation of nociceptors specific to individual diseases. This will shed insight on potential therapies for managing pain associated with autoimmune diseases.</p>","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":"959-977"},"PeriodicalIF":4.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
InflammopharmacologyPub Date : 2025-03-01Epub Date: 2025-02-19DOI: 10.1007/s10787-025-01662-9
Xiao-Feng Li, Xiongwu Yang, Hui Gao
{"title":"Activation of the NF-κB signaling pathway by Reynoutria japonica Houtt ameliorates complete Freund's adjuvant-induced arthritis in rats.","authors":"Xiao-Feng Li, Xiongwu Yang, Hui Gao","doi":"10.1007/s10787-025-01662-9","DOIUrl":"10.1007/s10787-025-01662-9","url":null,"abstract":"<p><strong>Background: </strong>Rheumatoid arthritis (RA) manifests through persistent synovitis and systemic inflammation, which ultimately result in the degradation of cartilage and bone. The current study was to scrutinize the anti-arthritic effect of Reynoutria japonica Houtt ameliorating complete Freund's adjuvant (CFA)-induced RA in rats and explore the underlying mechanism.</p><p><strong>Material and methods: </strong>CFA was used for the induction of RA in the rats (rats were received the oral administration of Reynoutria japonica Houtt) and estimation of body weight and organ weight. The paw volume, arthritic score, paw withdrawn threshold, and paw withdrawn latency were estimated at regular time. The RF, hematological, hepatic, non-hepatic, ATG, oxidative stress, cytokines, and inflammatory parameters were estimated. The mRNA expression of different genes was scrutinized.</p><p><strong>Results: </strong>Reynoutria japonica Houtt treatment improved the body weight and reduced the spleen and thymus index. Reynoutria japonica Houtt also suppressed the paw edema, arthritic score, paw withdrawn threshold, and paw withdrawn latency at regular time interval. Reynoutria japonica Houtt suppressed the RF and altered the hematological, hepatic, non-hepatic, cytokines and inflammatory parameters. Reynoutria japonica Houtt treatment significantly (P < 0.001) altered the expression of MMP-2, MMP-9, MMP-12, TNF-α, IL-1β, Il-6, IL-10, IL-17, COX-1, COX-2, NF-κB, iNOS, mTOR, LC3-II, AMPK, and Beclin 1.</p><p><strong>Conclusion: </strong>The result clearly stated the promising effect of Reynoutria japonica Houtt against CFA-induced RA in rats via the suppression of NF-κB signaling pathway.</p>","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":"1407-1424"},"PeriodicalIF":4.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143457677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
InflammopharmacologyPub Date : 2025-03-01Epub Date: 2025-02-15DOI: 10.1007/s10787-025-01659-4
Yan Zhang, Shaoying Yuan, Yixing Wu, Wenkai Nie, Tianhui You, Huiwen Yang, Bing Liu
{"title":"Advancements in pharmacological interventions for atopic dermatitis current strategies and future directions.","authors":"Yan Zhang, Shaoying Yuan, Yixing Wu, Wenkai Nie, Tianhui You, Huiwen Yang, Bing Liu","doi":"10.1007/s10787-025-01659-4","DOIUrl":"10.1007/s10787-025-01659-4","url":null,"abstract":"<p><p>Atopic dermatitis (AD) is a complex chronic inflammatory skin disorder, with its incidence significantly increasing in recent years. The pathogenesis of AD is complex, involving multiple factors such as genetic susceptibility, dysbiosis of the skin microbiome, autoimmune abnormalities, impaired epidermal barrier function, and environmental factors. These factors collectively contribute to the high incidence of the disease and its significant socio-economic burden. This article reviews the pathogenesis of AD and analyzes the current traditional treatment approaches, including topical and systemic therapies, highlighting the issues they face. It focuses on the current status and treatment strategies. Specifically, as the significant heterogeneity of AD, treatment paradigms are gradually shifting from a \"one-size-fits-all\" approach to personalized treatments. The aim is to achieve more effective management of AD and address the issues arising from individual differences. Through these discussions, this article aims to provide new perspectives and strategies for the clinical treatment of AD, in order to reduce the disease burden on patients.</p>","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":"1221-1236"},"PeriodicalIF":4.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
InflammopharmacologyPub Date : 2025-03-01Epub Date: 2025-02-08DOI: 10.1007/s10787-025-01648-7
Malati R Salunke, Vaibhav Shinde
{"title":"Molecular insights and efficacy of guava leaf oil emulgel in managing non diabetic as well as diabetic wound healing by reducing inflammation and oxidative stress.","authors":"Malati R Salunke, Vaibhav Shinde","doi":"10.1007/s10787-025-01648-7","DOIUrl":"10.1007/s10787-025-01648-7","url":null,"abstract":"<p><p>Wound healing in diabetic patients is often compromised due to excessive inflammation, oxidative stress, and impaired angiogenesis, leading to delayed recovery and increased susceptibility to complications. This study aimed to develop an emulgel formulation of guava leaf oil, derived from Psidium guajava (Myrtaceae), and evaluate its wound healing potential in nondiabetic and diabetic rats. Preliminary phytochemical analysis of guava leaf oil identified active compounds such as D-limonene, β-caryophyllene, and 1,8-cineole, which are known for their anti-inflammatory and antioxidant properties. The emulgel was formulated and assessed for physical attributes, including pH, viscosity, spreadability, and stability. The emulgel demonstrated potent antimicrobial activity, with the 1% concentration showing significant efficacy. In vivo studies revealed enhanced wound contraction in diabetic rats treated with the emulgel, supporting its role in promoting excision wound healing. These findings underscore the therapeutic potential of guava leaf oil emulgel as an effective agent for managing nondiabetic and diabetic wounds, providing a foundation for future clinical applications.</p>","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":"1491-1503"},"PeriodicalIF":4.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143373942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
InflammopharmacologyPub Date : 2025-03-01Epub Date: 2025-02-27DOI: 10.1007/s10787-025-01698-x
Omkar Kumar Kuwar, Nileshwar Kalia
{"title":"Anti-inflammatory and antioxidant effects of baicalein: targeting Nrf2, and NFĸB in neurodegenerative disease.","authors":"Omkar Kumar Kuwar, Nileshwar Kalia","doi":"10.1007/s10787-025-01698-x","DOIUrl":"10.1007/s10787-025-01698-x","url":null,"abstract":"<p><p>Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, are characterized by progressive loss of neurons in the brain regions, including the hippocampus, cortex, substantia nigra, and striatum. Multiple pathological mechanisms drive this neuronal loss, including oxidative stress, chronic inflammation, mitochondrial dysfunction, protein misfolding, and excitotoxicity. Recent evidence suggests that these processes are intricately linked to the dysregulation of key signalling pathways, such as the IĸB/NFĸB, and KEAP1/Nrf2 pathways, which play central roles in neuroinflammation, oxidative stress, and mitochondrial functions, respectively. At present, no cure exists for neurodegenerative disorders, and available medications focus solely on symptomatic management. While these treatments provide temporary relief, their long-term use is often associated with adverse health effects. In this context, natural Phytoactive constituents like Baicalein, a bioactive flavonoid derived from Scutellaria baicalensis, have gained attention for their promising therapeutic potential. Baicalein has been shown to modulate the IĸB/NFĸB, and KEAP1/Nrf2 pathways, thereby mitigating neuroinflammation and oxidative stress while supporting mitochondrial health. It exerts anti-inflammatory effects by inhibiting NFĸB activation, thereby reducing the production of proinflammatory cytokines, such as TNF-α, IL-1β, IL-6, and NLRP3 inflammasome, and enzymes like COX-2, LOX, and iNOS, which are essential for innate and adaptive immune responses. Simultaneously, baicalein enhances the Nrf2 activation, promoting the expression of antioxidant enzymes like HO-1, NQO1, GPx, and SOD, thus countering oxidative stress. These findings highlight the potential of baiclalein as a complementary approach for managing neurodegenerative diseases, offering a safer and more holistic alternative to conventional therapies.</p>","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":"1303-1310"},"PeriodicalIF":4.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
InflammopharmacologyPub Date : 2025-03-01Epub Date: 2025-02-26DOI: 10.1007/s10787-025-01674-5
Ozan Küçükatalay, Çağlar Türk, Çevik Gürel, Gökçe Ceren Kuşçu, Mustafa Eren Yüncü, İnanç Karakoyun, Murat Akşit, Onur Sarıkaya, Ali Karadağ, Mahmut Çamlar
{"title":"Certolizumab enhances spinal cord injury recovery in rats through inhibition of the TNF-α signaling pathway and neuronal apoptosis.","authors":"Ozan Küçükatalay, Çağlar Türk, Çevik Gürel, Gökçe Ceren Kuşçu, Mustafa Eren Yüncü, İnanç Karakoyun, Murat Akşit, Onur Sarıkaya, Ali Karadağ, Mahmut Çamlar","doi":"10.1007/s10787-025-01674-5","DOIUrl":"10.1007/s10787-025-01674-5","url":null,"abstract":"<p><strong>Objective: </strong>Spinal cord injury (SCI), which is characterized by motor and/or sensory dysfunction, presents a significant health challenge resulting from mechanical trauma. Secondary injury, which follows the mechanical trauma and is driven by factors such as inflammation, plays a critical role in the SCI pathophysiology. Scientific evidence indicates that treatment strategies aimed at modulating inflammation during the acute phase of SCI alleviate the seconder injury. In this regard, the present study seeks to evaluate the effectiveness of certolizumab, a monoclonal antibody targeting TNF-α that is widely used in the treatment of various inflammatory diseases, in a SCI model.</p><p><strong>Methods: </strong>In this study, Control, Trauma, and Trauma + Certolizumab groups were established, each comprising eight male rats. One hour after SCI induction, rats in the Trauma + Certolizumab group were administered 10 µg Certolizumab dissolved in saline intraperitoneally, while rats in the Control and Trauma groups received an equivalent volume of saline. After Modified Tarlov Scoring was performed on the seventh day of the experiment, all rats were sacrificed. The effects of certolizumab on neuroinflammation and apoptosis in the SCI model were evaluated using histological, biochemical, and molecular analyses of blood and tissue samples obtained from the rats.</p><p><strong>Results: </strong>Certolizumab downregulated the expression of TNF-α, NF-κB, and IL-6. In addition, as evidenced by the TUNEL assay, Caspase-3 expression (an apoptotic marker), and Modified Tarlov Score results, certolizumab effectively suppressed inflammation-induced neural apoptosis and alleviated locomotor deficits.</p><p><strong>Conclusion: </strong>Certolizumab treatment exerts a neuroprotective effect against secondary damage in SCI through the inhibition of neuroinflammation and apoptosis.</p>","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":"1517-1529"},"PeriodicalIF":4.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11914241/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143500829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
InflammopharmacologyPub Date : 2025-03-01Epub Date: 2025-02-05DOI: 10.1007/s10787-024-01631-8
Mohamed A Anwar, Ghadir A Sayed, Dina M Hal, Mohamed S Abd El Hafeez, Abdel-Aziz S Shatat, Aya Salman, Nehal M Eisa, Asmaa Ramadan, Riham A El-Shiekh, Shymaa Hatem, Shaza H Aly
{"title":"Herbal remedies for oral and dental health: a comprehensive review of their multifaceted mechanisms including antimicrobial, anti-inflammatory, and antioxidant pathways.","authors":"Mohamed A Anwar, Ghadir A Sayed, Dina M Hal, Mohamed S Abd El Hafeez, Abdel-Aziz S Shatat, Aya Salman, Nehal M Eisa, Asmaa Ramadan, Riham A El-Shiekh, Shymaa Hatem, Shaza H Aly","doi":"10.1007/s10787-024-01631-8","DOIUrl":"10.1007/s10787-024-01631-8","url":null,"abstract":"<p><p>Across diverse cultures, herbal remedies have been used to alleviate oral discomfort and maintain dental hygiene. This review presents studies on herbal remedies with remarkable antimicrobial, anti-inflammatory, antioxidant, anticancer, anticaries, analgesic, and healing properties. The manuscripts demonstrate the depth of scientific inquiry into herbal remedies used for the management of various oral and dental health conditions. These include gingivitis, oral ulcers, mucositis, periodontitis, oral pathogens, carcinoma, xerostomia, and dental caries. Researchers have investigated the phytochemical and pharmacological properties of plant-derived compounds and their extracts evaluated their interactions with oral pathogens and inflammatory processes. The convergence of traditional knowledge and rigorous scientific investigation offers a compelling narrative, fostering a deeper understanding of herbal remedies as viable alternatives to conventional dental interventions. This work has the potential to provide patients with access to gentle, yet effective solutions, and simultaneously offer dental health professionals the opportunity to enrich their knowledge, and ability to provide personalized, holistic care. This review highlights the symbiotic relationship between herbal medicine and scientific understanding, emphasizing the importance of disseminating this knowledge to benefit both practitioners and patients, enabling evidence-based decision-making in dental care. The exploration of herbal remedies offers a promising alternative, potentially mitigating some of these side effects while promoting oral health in a more natural and holistic manner.</p>","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":"1085-1160"},"PeriodicalIF":4.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11914039/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143189125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
InflammopharmacologyPub Date : 2025-03-01Epub Date: 2025-02-15DOI: 10.1007/s10787-025-01649-6
Taha Tavaci, Zekai Halici, Elif Cadirci, Mustafa Ozkaraca, Kamber Kasali
{"title":"The impact of tocilizumab treatment on the severity of inflammation and survival rates in sepsis is significantly influence by the timing of administration.","authors":"Taha Tavaci, Zekai Halici, Elif Cadirci, Mustafa Ozkaraca, Kamber Kasali","doi":"10.1007/s10787-025-01649-6","DOIUrl":"10.1007/s10787-025-01649-6","url":null,"abstract":"<p><strong>Background: </strong>Sepsis is a life-threatening organ dysfunction resulting from a dysregulated host response to infection. Due to the high mortality rates and treatment costs associated with sepsis, research is focusing on innovative treatment strategies to replace one dimensional approaches. Recent studies are being conducted on the use of immunotherapeutics in sepsis and the impact of treatment timing. This study aimed to elucidate the significance of treatment timing in sepsis immunotherapy with Tocilizumab (TCZ) and the implications of differences in treatment timing.</p><p><strong>Methods: </strong>LPS-induced sepsis model was established in rats to assess the changes in interleukin-6 (IL-6) over a 24-h sepsis period and its correlation with lung and kidney injury. The impact of TCZ treatments at various time points was evaluated by molecular and histopathological methods. The effect of TCZ treatment timing on survival was analyzed using Kaplan-Meier survival analysis.</p><p><strong>Results: </strong>IL-6 reached peak concentrations in the early stages of sepsis, whereas lung damage peaked subsequent to the IL-6 peak, and kidney damage manifested considerably later. The early treatment group, receiving intervention one hour post-sepsis induction, exhibited the most favorable molecular and histopathological outcomes. Conversely, the group receiving the latest treatment, at sixteen hours post-sepsis induction, demonstrated the poorest results. Survival analysis indicated that the group treated at the tenth hour exhibited the highest survival rate.</p><p><strong>Conclusion: </strong>Variations in the timing of sepsis treatment with TCZ yield significantly different molecular outcomes, histopathological results, and survival rates. A thorough investigation of the timing of immunotherapeutic applications in sepsis treatment will enhance the efficiency of sepsis treatments.</p>","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":"1393-1405"},"PeriodicalIF":4.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11914034/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
InflammopharmacologyPub Date : 2025-03-01Epub Date: 2025-02-11DOI: 10.1007/s10787-025-01647-8
Riham A El-Shiekh, Mai Hussin Radi, Essam Abdel-Sattar
{"title":"Unveiling the therapeutic potential of aromadendrin (AMD): a promising anti-inflammatory agent in the prevention of chronic diseases.","authors":"Riham A El-Shiekh, Mai Hussin Radi, Essam Abdel-Sattar","doi":"10.1007/s10787-025-01647-8","DOIUrl":"10.1007/s10787-025-01647-8","url":null,"abstract":"<p><p>In the dynamic realm of scientific inquiry, the identification and characterization of biologically active compounds derived from plant extracts have become of utmost significance. A particularly noteworthy flavonoid in this regard is aromadendrin (AMD), which can be found in a diverse range of foods, fruits, plants, and natural sources. The versatility of this compound is evident through its wide array of biological properties, including its well-documented anti-inflammatory, antioxidant, antidiabetic, neuroprotective, immunomodulatory, cardioprotective, and hepatoprotective effects. These diverse actions validate its potential utilization in addressing drug-related side effects, adverse reactions, neoplasms, ulcers, jaundice, diabetes mellitus, dermatitis, neurodegenerative diseases, cognitive disorders, polyploidy, carcinomas, common colds, and cumulative trauma disorders. This review aims to unlock the full potential of AMD and pave the way for groundbreaking advancements in the fields of medicine and nutrition. Prepare to embark on an enthralling journey as we unveil the hidden treasures and extraordinary prospects associated with AMD.</p>","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":"1209-1220"},"PeriodicalIF":4.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11914357/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143390842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}